Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment
    • J&J offers 2.1 billion...

    J&J offers 2.1 billion dollars to acquire Japan Cosmetics firm Ci:z

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-10-24T13:00:43+05:30  |  Updated On 24 Oct 2018 1:00 PM IST
    J&J offers 2.1 billion dollars to acquire Japan Cosmetics firm Ci:z

    TOKYO: U.S. healthcare conglomerate Johnson & Johnson had recently announced that it will buy all outstanding shares of Japanese skincare firm Ci:z Holdings Co Ltd that it does not already own for 230 billion yen ($2.05 billion) in cash.


    J&J is betting the deal - which will give it ownership of popular brands such as Dr.Ci:Labo, Labo Labo and Genomer - will help it strengthen its international innovation pipeline.


    The purchase adds to a flurry of cosmetics deals in Asia in recent years, as global brands seek to expand in a booming region that includes the $53.5 billion China market by leveraging Asian brands' smart online marketing and fast turnaround times for new products.

    France's L'Oreal SA agreed to buy South Korean makeup and fashion firm Nanda in May, and Unilever NV bought cosmetics firm Carver Korea for $2.7 billion last year. LVMH and Estee Lauder Companies Inc have also invested in South Korean cosmetics firms.

    J&J will pay 5,900 yen per Ci:z share, a 55 per cent premium over Tuesday's closing price, and also acquire the shares owned by the Japanese firm's founder Yoshinori Shirono, J&J said in a statement.

    CIC Corp, the founder's ownership vehicle, is the biggest shareholder of the dermo-cosmetics specialist with a 27.96 per cent interest, showed Refinitiv data.

    J&J is the second-largest shareholder, owning 19.9 per cent through an affiliate since 2016, allowing it to distribute Ci:z's brands outside of Japan. J&J expects the full acquisition will help it leverage the large consumer database of the collagen gel and medical skin products maker.

    "This transaction will maximise value creation ... by bringing in an agile innovation model and rapidly accelerating sales through our global commercialization expertise," Jorge Mesquita, worldwide chairman at Johnson & Johnson's consumer division, said in the statement.

    J&J, which has been selling businesses such as diabetes care devices to focus on better-performing units and product development, plans to launch the tender offer on Oct. 29.
    CIC CorpcosmeticsEstee Lauder CompaniesJapanJapanese skincare firmJohnson & JohnsonL'OrealLVMHUS healthcare
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok